Breaking News, Collaborations & Alliances

Enlivex, BeiGene Partner to Evaluate Allocetra/PD-1 Inhibitor Tislelizumab

Enlivex to amend ongoing Phase I/II trial in advanced-stage solid tumors to include evaluation of Allocetra in combination with tislelizumab.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, entered into a clinical collaboration with BeiGene to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors. “We are excited to explore the potential of Allocetra in combination with tislelizumab, a potentiall...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters